Label-free biosensing with singular-phase-enhanced lateral position shift based on atomically thin plasmonic nanomaterials

Shaodi Zhu,Rodolphe Jaffiol,Aurelian Crunteanu,Cyrille Vézy,Sik-To Chan,Wu Yuan,Ho-Pui Ho,Shuwen Zeng

DOI: https://doi.org/10.1038/s41377-023-01345-6

2024-01-01

Abstract:Abstract Rapid plasmonic biosensing has attracted wide attention in early disease diagnosis and molecular biology research. However, it was still challenging for conventional angle-interrogating plasmonic sensors to obtain higher sensitivity without secondary amplifying labels such as plasmonic nanoparticles. To address this issue, we developed a plasmonic biosensor based on the enhanced lateral position shift by phase singularity. Such singularity presents as a sudden phase retardation at the dark point of reflection from resonating plasmonic substrate, leading to a giant position shift on reflected beam. Herein, for the first time, the atomically thin layer of Ge 2 Sb 2 Te 5 (GST) on silver nanofilm was demonstrated as a novel phase-response-enhancing plasmonic material. The GST layer was not only precisely engineered to singularize phase change but also served as a protective layer for active silver nanofilm. This new configuration has achieved a record-breaking largest position shift of 439.3 μm measured in calibration experiments with an ultra-high sensitivity of 1.72 × 10 8 nm RIU −1 (refractive index unit). The detection limit was determined to be 6.97 × 10 −7 RIU with a 0.12 μm position resolution. Besides, a large figure of merit (FOM) of 4.54 × 10 11 μm (RIU∙°) −1 was evaluated for such position shift interrogation, enabling the labelfree detection of trace amounts of biomolecules. In targeted biosensing experiments, the optimized sensor has successfully detected small cytokine biomarkers (TNF-α and IL-6) with the lowest concentration of 1 × 10 −16 M. These two molecules are the key proinflammatory cancer markers in clinical diagnosis, which cannot be directly screened by current clinical techniques. To further validate the selectivity of our sensing systems, we also measured the affinity of integrin binding to arginylglycylaspartic acid (RGD) peptide (a key protein interaction in cell adhesion) with different Mn 2+ ion concentrations, ranging from 1 nM to 1 mM.

optics

What problem does this paper attempt to address?

The paper primarily addresses the need for high-sensitivity, label-free biosensing technology in early disease diagnosis and molecular biology research. Specifically, the paper proposes a new solution to the challenge faced by traditional surface plasmon resonance (SPR)-based biosensors, which struggle to achieve higher sensitivity without secondary amplification labels.

The main contributions of the paper include:

1. **Design and Implementation of a Novel Biosensor**: Researchers developed a biosensor based on phase singularity-enhanced lateral position shift (Goos-Hänchen shift). This sensor utilizes a combination of atomically thin Ge₂Sb₂Te₅ (GST) film and silver nanofilm to achieve significant phase change enhancement, resulting in a substantial shift in the position of the reflected light beam.
2. **High Sensitivity and Detection Limit**: Through optimized design, the sensor achieved a record maximum position shift of 439.3 micrometers in experiments, with ultra-high sensitivity (1.72 × 10^8 nm RIU⁻¹). The detection limit was determined to be 6.97 × 10⁻⁷ RIU, and the position resolution reached 0.12 micrometers.
3. **Label-Free Detection of Trace Biomolecules**: The newly configured sensor can achieve label-free detection of trace biomolecules and successfully detected key inflammatory cancer markers—tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6)—at concentrations as low as 1 × 10⁻¹⁶ M. These markers cannot be directly screened in early clinical diagnosis.
4. **Validation of Selectivity and Affinity**: To further validate the sensor's selectivity and specificity, researchers also measured the affinity between integrin and arginylglycylaspartic acid (RGD) peptide, demonstrating the sensor's real-time monitoring capability at different Mn²⁺ ion concentrations.

In summary, the technology proposed in this paper not only significantly improves the sensitivity and detection capability of biosensing but also shows potential applications in clinical diagnostics and fundamental biological research.